Roche Holding AG Ordinary Shares new ROP

Morningstar Rating
CHF 345.70 −3.30 (0.95%)
View Full Chart

Company Report

Roche's Combination of Innovation and Diversification Warrant a Wide Moat

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare giant is uniquely positioned to guide global healthcare toward a safer, more personalized, and more cost-effective future. Strong information sharing continues between Genentech and Roche researchers, boosting research and development productivity and personalized medicine offerings that leverage Roche's diagnostic expertise and leadership in artificial intelligence.

Price vs Fair Value

ROP is trading within a range we consider fairly valued.
Price
CHF 345.70
Fair Value
LOCK|?P
Uncertainty
LOCK|Rc
1-Star Price
LOCK|c.XXl
5-Star Price
LOCK|t.p
Economic Moat
LOCK|>?@
Capital Allocation
LOCK|$MD%^?g

Bulls Say, Bears Say

Bulls

Roche and its innovative US arm Genentech have a solid history of generating blockbuster therapies in oncology, and Roche's pipeline is full of novel candidates, with a particularly large late-stage pipeline.

Bears

Roche's immuno-oncology drug Tecentriq was launched third to market behind Bristol's Opdivo and Merck's Keytruda, raising questions about Roche's innovation.

News

Trading Information

Previous Close Price
CHF 349.00
Day Range
CHF 342.50–349.90
52-Week Range
CHF 258.20–375.80
Bid/Ask
CHF 0.00 / CHF 0.00
Shares Outstanding
796.77M
Market Cap
CHF 275.44B
Volume/Avg
660,395 / 892,813

Key Statistics

Price/Earnings (Normalized)
19.44
Price/Sales
4.46
Dividend Yield (Trailing)
2.83%
Dividend Yield (Forward)
2.83%
Dividend Payment Schedule
Mar
Total Yield
2.83%

Company Profile

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
112,774

Competitors

Valuation

Metric
ROP
MRK
ABBV
Price/Earnings (Normalized)
19.4444.8023.91
Price/Book Value
8.518.47—
Price/Sales
4.465.367.16
Price/Cash Flow
13.9716.1019.73
Price/Earnings
ROP
MRK
ABBV

Financial Strength

Metric
ROP
MRK
ABBV
Quick Ratio
0.800.710.49
Current Ratio
1.231.320.81
Interest Coverage
13.494.283.89
Quick Ratio
ROP
MRK
ABBV

Profitability

Metric
ROP
MRK
ABBV
Return on Assets (Normalized)
15.81%6.27%14.29%
Return on Equity (Normalized)
48.77%16.68%—
Return on Invested Capital (Normalized)
23.90%9.82%32.02%
Return on Assets
ROP
MRK
ABBV

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
LOCK|jd<@#^?LOCK|Jg?$1T
Johnson & Johnson
JNJ
LOCK|b##f@yzLOCK|Nx?$623B
AbbVie Inc
ABBV
LOCK|QRdDB#LOCK|&J$459B
Merck & Co Inc
MRK
LOCK|S?$$L#MLOCK|Xd$355B
Roche Holding AG ADR
RHHBY
LOCK|mpb<&lQLOCK|&@F$334B
Novartis AG ADR
NVS
LOCK|BxPPn!YLOCK|q&<$268B
AstraZeneca PLC
AZN
LOCK|#ljk<^PJLOCK|sK$248B
Amgen Inc
AMGN
LOCK|nXTkgYpLOCK|#?$220B
Gilead Sciences Inc
GILD
LOCK|?%^Y^>xLOCK|$?$183B
Novo Nordisk AS ADR
NVO
LOCK|%H!n&ycLOCK|L@$167B

Sponsor Center